1619 related articles for article (PubMed ID: 24373340)
1. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
Albert NM
Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
[TBL] [Abstract][Full Text] [Related]
3. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
4. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Miller CS; Grandi SM; Shimony A; Filion KB; Eisenberg MJ
Am J Cardiol; 2012 Aug; 110(3):453-60. PubMed ID: 22537354
[TBL] [Abstract][Full Text] [Related]
6. A review of oral anticoagulants in patients with atrial fibrillation.
Greenspon AJ
Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
[TBL] [Abstract][Full Text] [Related]
7. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
8. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
9. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
11. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
Aguilar MI; Kuo RS; Freeman WD
Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
[TBL] [Abstract][Full Text] [Related]
12. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
13. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Lenchus JD
Hosp Pract (1995); 2013 Feb; 41(1):49-60. PubMed ID: 23466967
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
16. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
[TBL] [Abstract][Full Text] [Related]
17. New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
Bhimani AA; Hong M
Rev Recent Clin Trials; 2013 Jun; 8(2):78-85. PubMed ID: 23859143
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Harrington AR; Armstrong EP; Nolan PE; Malone DC
Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
[TBL] [Abstract][Full Text] [Related]
19. ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Tendera M; Syzdół M; Parma Z
Cardiol J; 2012; 19(1):4-10. PubMed ID: 22298161
[TBL] [Abstract][Full Text] [Related]
20. [Improvements in oral anticoagulant therapy for atrial fibrillation].
Briongos Figuero S; García Santos-Gallego C; Badimón JJ
Med Clin (Barc); 2013 Dec; 141(11):487-93. PubMed ID: 23597953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
